On Nov 09, major Wall Street analysts update their ratings for $PTC Therapeutics (PTCT.US)$, with price targets ranging from $45 to $48.
Morgan Stanley analyst Jeffrey Hung maintains with a hold rating, and maintains the target price at $45.
BofA Securities analyst Tazeen Ahmad maintains with a sell rating.
Baird analyst Joel Beatty maintains with a buy rating, and adjusts the target price from $44 to $48.
William Blair analyst Sami Corwin maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $PTC Therapeutics (PTCT.US)$'s main analysts recently are as follows:
PTC Therapeutics is noted for its consistent execution, with significant milestones such as Upstaza's PDUFA date approaching on November 13th and the anticipated launch of sepiapterin in July 2025. Approval for both products is expected by the analyst.
PTC Therapeutics' third-quarter revenue surpassed expectations significantly, partly because of sustained sales of Emflaza, even though it now faces generic competitors.
Here are the latest investment ratings and price targets for $PTC Therapeutics (PTCT.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
